Grufity logo
Grufity logo
ETON

ETON - Eton Pharmaceuticals Inc Stock Price, Fair Value and News

$32.35+0.20 (+0.62%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

32/100

ETON

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

32/100

ETON

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ETON Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ETON Price Action

Last 7 days

7.3%

Last 30 days

6.2%

Last 90 days

69.9%

Trailing 12 Months

124.8%

ETON RSI Chart

ETON Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ETON Valuation

Market Cap

879.6M

Price/Earnings (Trailing)

-596.35

Price/Sales (Trailing)

10.12

EV/EBITDA

137.81

Price/Free Cashflow

57

ETON Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ETON Fundamentals

ETON Revenue

Revenue (TTM)

86.9M

Rev. Growth (Yr)

40.41%

Rev. Growth (Qtr)

14.03%

ETON Earnings

Earnings (TTM)

-1.5M

Earnings Growth (Yr)

198.85%

Earnings Growth (Qtr)

4.79%

ETON Profitability

Operating Margin

96.98%

EBT Margin

-1.71%

Return on Equity

-4.82%

Return on Assets

-1.51%

Free Cashflow Yield

1.75%

ETON Investor Care

Shares Dilution (1Y)

2.02%

ETON Alerts

  • 2 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202686.9M---
202548.3M58.2M70.3M80.0M
202434.3M31.4M34.7M39.0M
202324.4M29.0M32.8M31.6M
202212.1M16.4M18.8M21.3M
202112.9M15.9M18.9M21.8M
20203.9M6.9M-9.9M
2019561.5K--959.0K
2018---164.0K
2017----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Eton Pharmaceuticals Inc

ETON
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and dehydrated alcohol injection to treat methanol poisoning. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis; Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis; EPRONTIA, a liquid formulation of topiramate; ZONISADE, a liquid formulation of zonisamide for the treatment of partial seizures in patients with epilepsy; and Lamotrigine for Oral Suspension for the treatment of epilepsy. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
 CEO
 WEBSITEetonpharma.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES28

Eton Pharmaceuticals Inc Frequently Asked Questions

ETON is the stock ticker symbol of Eton Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Eton Pharmaceuticals Inc is 879.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, ETON's PE ratio (Price to Earnings) is -596.35 and Price to Sales (PS) ratio is 10.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ETON PE ratio will change depending on the future growth rate expectations of investors.